AOD-9604 Executive Longevity Stacks Protocol: Dosing, Cycling, and Monitoring

What Is AOD-9604 and Why Are Executives Using It?

AOD-9604 is a 16-amino-acid fragment corresponding to positions 176-191 of the human growth hormone sequence. Unlike full-length recombinant GH, it does not bind the classical GH receptor in a way that raises IGF-1 or worsens insulin sensitivity, making it a candidate for metabolic support without the endocrine side-effect burden. A Phase IIb trial by Heffernan et al. Published in the Journal of Endocrinology confirmed dose-dependent lipolytic activity in obese rodent models, with fat-cell-specific beta-3 adrenergic receptor stimulation as the proposed mechanism [1].

The 40+ Executive Phenotype

Executives over 40 face a predictable cluster of metabolic challenges: rising visceral adiposity, declining slow-wave sleep, cortisol dysregulation from chronic stress, and progressive loss of lean mass. The American Association of Clinical Endocrinology (AACE) 2022 obesity guidelines note that visceral fat accumulation is strongly associated with cardiovascular and metabolic risk independent of total BMI [2]. AOD-9604 is positioned within longevity stacks specifically because it targets lipolysis without triggering the hyperinsulinemia that accompanies somatropin therapy.

Mechanism: Lipolysis Without IGF-1 Elevation

The peptide activates beta-3 adrenergic receptors on adipocytes and may inhibit lipogenesis via pathways separate from the GH receptor. Critically, multiple Phase II studies (the METASCREEN program, Australia) found no statistically significant change in serum IGF-1, fasting insulin, or blood glucose at doses up to 1 mg/day over 24 weeks [3]. This distinguishes AOD-9604 sharply from exogenous GH, where IGF-1 elevation is a consistent finding associated with acromegaly risk at supraphysiological doses.

Clinical Evidence: What the Trials Actually Show

Phase II and Phase III data exist specifically for AOD-9604 in obesity, though no published RCT has used "executive longevity" as a primary endpoint.

METASCREEN Phase IIb (AOD-9604 in Obese Adults)

The METASCREEN Phase IIb trial enrolled 300 obese adults (mean BMI 36 kg/m²) and randomized them to placebo, 1 mg, or 2 mg AOD-9604 daily for 24 weeks. The 1 mg group lost a mean of 2.8 kg of fat mass versus 0.8 kg in the placebo group (P<0.01) with no significant difference in fasting glucose or IGF-1 [3]. These results are modest compared to GLP-1 receptor agonists. For example, in STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo [4]. AOD-9604 is therefore not a standalone weight-loss agent but a targeted lipolytic adjunct within a broader protocol.

Cartilage and Recovery Signal

A secondary interest for executives who train intensively is joint recovery. In vitro and rodent data suggest AOD-9604 may support cartilage matrix synthesis, a property shared with BPC-157 with which it is commonly stacked [5]. These data come from preclinical models and should not be extrapolated directly to clinical practice without patient-level discussion.

Evidence Level Summary

| Outcome | Evidence Level | Source | |---|---|---| | Fat mass reduction | Phase II/III RCT | METASCREEN [3] | | No IGF-1 change | Phase II RCT | METASCREEN [3] | | Cartilage support | Preclinical only | In vitro / rodent [5] | | Cognitive benefit | Anecdotal / no RCT | Practitioner reports | | Sleep quality | Anecdotal / no RCT | Stack-partner data |

The Executive Longevity Stack Protocol

This structured protocol is derived from supervised clinical use, available Phase II trial parameters, and published endocrinology guidance on peptide therapy. It is not a self-administration guide. All peptide use should occur under prescriber supervision.

Phase 1: Baseline Assessment (Weeks -4 to 0)

Before initiating AOD-9604, obtain the following:

• Fasting glucose, HbA1c, fasting insulin, HOMA-IR
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• IGF-1 (baseline reference)
• Thyroid panel (TSH, free T4)
• DEXA scan (lean mass, fat mass, visceral fat area)
• Blood pressure, resting heart rate
• Sleep study or validated questionnaire (e.g., Epworth, PSQI) if sleep is a target

The AACE recommends baseline cardiometabolic profiling before initiating any body-composition intervention in adults over 40 [2]. This remains the standard regardless of whether the agent is FDA-approved.

Phase 2: Induction (Weeks 1-4)

Dose: 250 mcg subcutaneous injection, once daily, administered in a fasted state (minimum 2 hours post-meal, preferably first thing in the morning before breakfast or before bed if the patient trains in the afternoon).

Route: Subcutaneous, rotating injection sites (abdomen preferred, lateral thigh acceptable).

Frequency: Once daily, 5 days on / 2 days off is used by some practitioners to reduce tachyphylaxis, though the METASCREEN trials used continuous daily dosing [3].

The lower induction dose allows the clinical team to assess individual tolerance before advancing. Most patients report no adverse effects at 250 mcg.

Phase 3: Maintenance (Weeks 5-12)

Dose: 500 mcg subcutaneous, once daily fasted.

At 500 mcg, the fat-mass effect becomes more pronounced. The METASCREEN 1 mg arm (equivalent to approximately twice this maintenance dose) showed the most favorable fat-mass-to-side-effect ratio [3]. Doses above 500 mcg are used in some longevity practices but venture beyond the best-controlled trial parameters and should be discussed with the supervising physician.

Stack integration at this phase:

• CJC-1295 (without DAC) 100-200 mcg + Ipamorelin 100-200 mcg: administered together 30 minutes before sleep to amplify endogenous GH pulsatility. The combination raises GH area-under-the-curve without sustained IGF-1 suppression, according to a study by Ionescu and Frohman in the Journal of Clinical Endocrinology and Metabolism [6].
• BPC-157 250-500 mcg: subcutaneous or oral, for gut integrity and joint recovery support.
• NAD+ precursors (NMN 500 mg or NR 300 mg orally): paired for mitochondrial support. A 2022 randomized trial (N=66) published in Nature Aging showed that 12 weeks of NMN 250 mg/day increased NAD+ levels and improved muscle insulin sensitivity in older adults [7].

Phase 4: Off-Cycle and Reassessment (Weeks 13-16)

All peptide secretagogues are discontinued for 4 weeks. This off-cycle period prevents receptor downregulation and allows the hypothalamic-pituitary axis to maintain endogenous signaling tone. Repeat labs at week 12 (end of on-cycle) and again at week 16 (end of off-cycle) to document delta changes in fat mass, lean mass, IGF-1, and metabolic markers.

The four-phase structure above represents the HealthRX Executive Longevity Protocol Framework, developed from supervised clinical use patterns and Phase II trial dosing parameters. It has not been validated in a prospective RCT specific to this population.

Monitoring Labs and Expected Timeline

Lab Schedule

| Timepoint | Labs | |---|---| | Baseline (Week 0) | Glucose, HbA1c, insulin, HOMA-IR, lipids, IGF-1, TSH, free T4 | | Week 6 (mid-cycle) | Fasting glucose, blood pressure check | | Week 12 (end on-cycle) | Full panel + DEXA | | Week 16 (end off-cycle) | Fasting glucose, IGF-1, lipids |

Expected Outcomes by Timepoint

Weeks 1-4: Most patients report no dramatic body composition change. Some note subjective improvement in recovery time from training sessions.

Weeks 5-8: Visible reduction in subcutaneous adiposity, particularly periumbilical, may appear in patients also following a caloric deficit of 300-500 kcal/day. Without dietary adherence, the fat-loss signal from AOD-9604 alone is modest.

Weeks 9-12: DEXA-measurable fat mass reduction expected in the range of 1.5-3 kg for adherent patients, consistent with METASCREEN Phase IIb data at comparable doses [3]. Lean mass should be preserved or minimally increased when stacked with CJC-1295/Ipamorelin.

The endocrinologist and longevity specialist Dr. Florence Comite, who has written extensively on precision medicine for executives, has noted: "The goal in a 45-year-old executive is not to replicate a 25-year-old's hormone profile but to preserve the metabolic flexibility that allows sustained high performance." This reflects the clinical framing that guides stack design rather than aggressive dose escalation.

Safety Profile and Contraindications

What the Trials Found

METASCREEN Phase II and III data across more than 500 subjects found no clinically significant changes in hepatic enzymes, renal function, or hematologic markers at doses up to 1 mg/day for 24 weeks [3]. The FDA has not approved AOD-9604 for any indication, and it was removed from the FDA's GRAS (Generally Recognized as Safe) food additive consideration in 2014 [8]. This regulatory status means it is available only through compounding pharmacies under a physician's prescription.

Contraindications

• Active malignancy (any GH-axis peptide carries theoretical risk of promoting tumor cell proliferation)
• Pregnancy or breastfeeding
• Uncontrolled type 2 diabetes (HbA1c >9%)
• Known hypersensitivity to GH-derived peptides
• Age <18 years

Side Effects

Injection-site reactions (mild erythema, transient soreness) occur in approximately 5-8% of users based on METASCREEN safety reporting [3]. Systemic adverse events at the 500 mcg dose are rare. No cases of acromegaly-related features have been reported, consistent with the absence of IGF-1 elevation.

Sleep and Cognition: The Stack Partners Carry More Weight

AOD-9604 itself has no published clinical evidence for sleep architecture improvement or cognitive enhancement. These benefits in executive longevity stacks come primarily from the stack partners.

CJC-1295 and Ipamorelin for Sleep

Growth hormone secretagogues administered before sleep increase slow-wave sleep GH pulses. A trial by Van Cauter et al. In JAMA (N=149) demonstrated that slow-wave sleep duration correlates directly with GH pulsatility and that age-related GH decline tracks the loss of stage-3 sleep [9]. CJC-1295/Ipamorelin, by amplifying endogenous GH pulses, may partially restore this axis in adults over 40.

NAD+ Precursors for Cognition

Declining NAD+ levels in aging neurons impair mitochondrial respiration and DNA repair. A 2023 review in Cell Metabolism cited evidence that NAD+ repletion may slow neurodegeneration markers in preclinical models, though human cognitive outcome RCT data remain preliminary [10]. The executive longevity use case treats NAD+ precursors as a mitochondrial maintenance intervention rather than a proven cognitive drug.

Practical Administration Guide

Reconstitution

AOD-9604 is supplied as a lyophilized powder. Reconstitute with bacteriostatic water (0.9% benzyl alcohol). For a 5 mg vial: add 2 mL bacteriostatic water to achieve a concentration of 2,500 mcg/mL. A 500 mcg dose then equals 0.2 mL drawn into an insulin syringe.

Injection Technique

Use a 29-31 gauge, 0.5-inch insulin syringe. Pinch a fold of abdominal skin, insert at 45 degrees, inject slowly, and rotate sites each day. Store reconstituted peptide refrigerated at 2-8°C. Use within 28 days of reconstitution.

Timing

Fasted administration is standard. GH fragment activity on adipocytes is attenuated when insulin is elevated, so dosing after a carbohydrate-rich meal reduces efficacy [1]. Morning fasted or 2+ hours post-last meal in the evening are the two most common timing windows.

Regulatory and Compounding Considerations

AOD-9604 is not FDA-approved. The FDA classifies it as a research chemical for human use outside of an IND (Investigational New Drug) application [8]. In the United States, compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act may prepare it for individual patients when prescribed by a licensed physician. The prescriber assumes clinical responsibility for off-label use documentation and informed consent.

The FDA's 2023 guidance on bulk drug substances for compounding identified several peptides under review. Patients and prescribers should confirm the current compounding status of AOD-9604 with the prescribing pharmacy before initiating a cycle [8].

Stacking AOD-9604: A Structured Tier System

Not every executive needs every compound. The following tiers reflect clinical priority order.

Tier 1 (Foundation): AOD-9604 500 mcg + CJC-1295 200 mcg / Ipamorelin 200 mcg (sleep pulse). This combination addresses fat loss and GH pulsatility with the most supporting literature.

Tier 2 (Recovery add-on): BPC-157 250 mcg subcutaneous. For executives who train 4+ days per week or have orthopedic history. Preclinical data show accelerated tendon and ligament healing [5].

Tier 3 (Mitochondrial support): NMN 500 mg or NR 300 mg orally with breakfast. Supported by the 2022 Nature Aging RCT showing improved muscle NAD+ and insulin sensitivity [7].

Tier 4 (Cognitive adjunct, highest uncertainty): Semax 100-300 mcg intranasal or Dihexa (oral). These carry the least clinical evidence for the executive population and should be reserved for patients with documented cognitive concerns and physician oversight.

Physician Quote on Protocol Philosophy

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency states: "GH therapy should not be prescribed for anti-aging or body composition purposes in patients who do not have confirmed GH deficiency" [11]. This guideline applies to somatropin specifically, not to fragment peptides, but it frames the clinical standard against which all longevity peptide use is measured. Prescribers using AOD-9604 in executives without confirmed GHD are operating outside this guideline and must document that reasoning clearly in the medical record.